Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Health Care Supplies

Cytori Therapeutics Inc

+ Add to Watchlist

CYTX:US

0.6607 USD 0.0074 1.11%

As of 09:59:38 ET on 05/27/2015.

Snapshot for Cytori Therapeutics Inc (CYTX)

Open: 0.6760 Day's Range: 0.6550 - 0.6760 Volume: 127,427
Previous Close: 0.6681 52wk Range: 0.3627 - 2.5400 1-Yr Rtn: -73.26%

Stock Chart for CYTX

No chart data available.
  • CYTX:US 0.6606
  • 1D
  • 1M
  • 1Y
0.6681
Interactive CYTX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CYTX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.5645
Est. EPS (USD) (12/2015) -0.2640
Est. PEG Ratio -
Market Cap (M USD) 93.02
Shares Outstanding (M) 139.24
30 Day Average Volume 2,981,396
Price/Book (mrq) -
Price/Sale (ttm) 10.7855
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CYTX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CYTX

Cytori Therapeutics, Inc. discovers and develops cell-based therapeutics utilizing adult stem cells derived from fat tissue. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery.

Marc H HedrickPres/CEO/Principal Financial OfcrSeijiro Norio ShirahamaPresident:Asia Pacific
Steven KestenExec VP/Chief Medical OfficerTiago GiraoVP:Finance/CFO
More Company Profile & Key Executives for CYTX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil